# NGS identifies novel HLA-DQA1 and DPB1 associations with aplastic anemia in the Kazakhstani population

**Authors:** Aida Turganbekova, Zhulduz Zhanzakova, Perizat Kanabekova, Dana Baimukasheva, Zhazira Saduakas, Didara Khamitova, Saniya Abdrakhmanova, Zhaksylyk Masalimov, Wassim Y. Almawi

PMC · DOI: 10.3389/fimmu.2026.1752687 · Frontiers in Immunology · 2026-02-05

## TL;DR

This study finds that specific HLA Class II alleles are strongly linked to aplastic anemia risk in the Kazakhstani population, highlighting the need for region-specific genetic profiling.

## Contribution

The study reports novel HLA-DQA1 and DPB1 associations with aplastic anemia in the Kazakhstani population for the first time.

## Key findings

- Class II alleles showed stronger associations with aplastic anemia than Class I alleles in the Kazakhstani population.
- Novel HLA-DQA1 and DPB1 alleles were identified with strong effect sizes (ORs >69) for increased or reduced AA risk.
- Region-specific genetic profiling is needed to improve risk assessment and treatment strategies for aplastic anemia.

## Abstract

Aplastic anemia (AA) is a rare but serious blood disorder defined by autoimmune-driven destruction of bone marrow stem and progenitor cells. HLA polymorphisms are AA risk factors, with population-specific associations influencing disease susceptibility, treatment response, and transplant outcomes. While the genetic pathways driving AA development remain incompletely elucidated, a link between HLA variants and AA predisposition has been documented across diverse ethnic groups, though not in Central Asian communities, particularly in Kazakhstan.

We investigated the relationship between HLA Class I and Class II alleles and the risk of AA in the Kazakhstani population using high-resolution NGS genotyping.

The study included 91 patients with AA and 250 unrelated controls selected from the national registry of hematopoietic stem cell donors. HLA class I (A/C/B) and class II (DRB1/DQA1/DQB1/DPB1) high-resolution genotyping was conducted using NGS. Statistical significance was assessed with chi-square tests.

Class II alleles showed stronger associations with AA than Class I alleles. Novel HLA associations with strong effect sizes (ORs >69) were identified, including the first-ever reported associations between HLA-DQA1 alleles and AA susceptibility. DRB1*05:05:01, DRB1*01:02:01, DQA1*05:05:01, DQA1*03:03:01, DQA1*03:02:01, DQA1*01:04:01, DQB1*02:02:01, DPB1*02:01:02, and DPB1*104:01:01 were associated with a higher AA risk in the Kazakhstani population. In contrast, DRB1*07:01:01, DRB1*15:01:01, DQA1*03:01:01, DQA1*01:01:01, DQA1*05:01:01, DQB1*02:01:01, and DPB1*02:01:01 were linked with reduced risk. Among Class I alleles, only B*40:02:01 showed a weak association with increased AA risk (p = 0.042), markedly lower than the strong Class II effects.

Class II alleles, including those within DQA1 and DPB1, are important genetic factors influencing AA susceptibility in Kazakhstan. It highlights the need for region-specific genetic profiling to improve disease risk assessment and guide therapeutic strategies.

## Linked entities

- **Genes:** HLA-DQA1 (major histocompatibility complex, class II, DQ alpha 1) [NCBI Gene 3117], HLA-DPB1 (major histocompatibility complex, class II, DP beta 1) [NCBI Gene 3115], HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123], HLA-DQB1 (major histocompatibility complex, class II, DQ beta 1) [NCBI Gene 3119], HLA-B (major histocompatibility complex, class I, B) [NCBI Gene 3106]
- **Diseases:** aplastic anemia (MONDO:0013879)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, HLA-DPB1 (major histocompatibility complex, class II, DP beta 1) [NCBI Gene 3115] {aka DPB1, HLA-DP, HLA-DP1B, HLA-DPB}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, HLA-DQA1 (major histocompatibility complex, class II, DQ alpha 1) [NCBI Gene 3117] {aka CELIAC1, DQ-A1, DQA1, HLA-DQA, HLA-DQA1*}, HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123] {aka DRB1, HLA-DR1B, HLA-DRB, SS1}, HLA-DQB1 (major histocompatibility complex, class II, DQ beta 1) [NCBI Gene 3119] {aka CELIAC1, HLA-DQB, IDDM1}, HLA-B (major histocompatibility complex, class I, B) [NCBI Gene 3106] {aka AS, B-4901, HLAB}
- **Diseases:** blood disorder (MESH:D006402), viral hepatitis (MESH:D014777), congenital marrow failure syndromes (MESH:D000080984), ALL (MESH:D054198), AA (MESH:D000741), autoimmune, infectious, and hematologic diseases (MESH:D003141), autoimmune or chronic inflammatory conditions (MESH:D002908), paroxysmal nocturnal hemoglobinuria (MESH:D006457), Agranulocytosis (MESH:D000380), inflammatory (MESH:D007249), PK (MESH:C564858), pancytopenia (MESH:D010198), immune-mediated marrow injury (MESH:C567355), autoimmune (MESH:D001327), autoimmune bone marrow failure disorders (MESH:D000080983), myelodysplastic syndrome (MESH:D009190), hematological malignancies (MESH:D019337)
- **Chemicals:** agarose (MESH:D012685), EDTA (MESH:D004492)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12916586/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12916586/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12916586/full.md

---
Source: https://tomesphere.com/paper/PMC12916586